The introduction of therapies such as proteasome inhibitors (PIs), immunomodulator (IMiDs), and CD38 monoclonal antibodies has significantly improved the prognosis of MM; however, MM remains incurable, and almost all MM patients eventually experience relapse. Here, CD38 is linked to Miyoshi myopathy.